Loading...
Population cancer screening aims to balance benefits and harms in average-risk populations. Whether risk-based strategies can safely individualize breast cancer screening is uncertain. Two early publications from the ongoing WISDOM trial, which aims to test risk-based breast cancer screening, report the preliminary results and a secondary analysis of genetic risk variants.
Roughly 28,000 U.S. women aged 40–74 years with no history of breast cancer were randomized to annual mammography or risk-based screening integrating clinical and salivary-based genetic susceptibility testing. Risk-based screening recommendations varied by category:
High risk (≥6% 5-year risk): intensified screening with alternating mammography and MRI every 6 months…